Impact of neoadjuvant chemoradiotherapy on the local recurrence and distant metastasis pattern of locally advanced rectal cancer: a propensity score-matched analysis.
Journal
Chinese medical journal
ISSN: 2542-5641
Titre abrégé: Chin Med J (Engl)
Pays: China
ID NLM: 7513795
Informations de publication
Date de publication:
15 Sep 2021
15 Sep 2021
Historique:
entrez:
23
9
2021
pubmed:
24
9
2021
medline:
25
9
2021
Statut:
epublish
Résumé
Previous studies have demonstrated different predominant sites of distant metastasis between patients with and without neoadjuvant chemoradiotherapy (NCRT). This study aimed to explore whether NCRT could influence the metastasis pattern of rectal cancer through a propensity score-matched analysis. In total, 1296 patients with NCRT or post-operative chemoradiotherapy (PCRT) were enrolled in this study between January 2008 and December 2015. Propensity score matching was used to correct for differences in baseline characteristics between the two groups. After propensity score matching, the metastasis pattern, including metastasis sites and timing, was compared and analyzed. After propensity score matching, there were 408 patients in the PCRT group and 245 patients in the NCRT group. NCRT significantly reduced local recurrence (4.1% vs. 10.3%, P = 0.004), but not distant metastases (28.2% vs. 27.9%, P = 0.924) compared with PCRT. In both the NCRT and PCRT groups, the most common metastasis site was the lung, followed by the liver. The NCRT group developed local recurrence and distant metastases later than the PCRT group (median time: 29.2 [18.8, 52.0] months vs. 18.7 [13.3, 30.0] months, Z = -2.342, P = 0.019; and 21.2 [12.2, 33.8] vs. 16.4 [9.3, 27.9] months, Z = -1.765, P = 0.035, respectively). The distant metastases occurred mainly in the 2nd year after surgery in both the PCRT group (39/114, 34.2%) and NCRT group (21/69, 30.4%). However, 20.3% (14/69) of the distant metastases appeared in the 3rd year in the NCRT group, while this number was only 13.2% (15/114) in the PCRT group. The predominant site of distant metastases was the lung, followed by the liver, for both the NCRT group and PCRT group. NCRT did not influence the predominant site of distant metastases, but the NCRT group developed local recurrence and distant metastases later than the PCRT group. The follow-up strategy for patients with NCRT should be adjusted and a longer intensive follow-up is needed.
Sections du résumé
BACKGROUND
BACKGROUND
Previous studies have demonstrated different predominant sites of distant metastasis between patients with and without neoadjuvant chemoradiotherapy (NCRT). This study aimed to explore whether NCRT could influence the metastasis pattern of rectal cancer through a propensity score-matched analysis.
METHODS
METHODS
In total, 1296 patients with NCRT or post-operative chemoradiotherapy (PCRT) were enrolled in this study between January 2008 and December 2015. Propensity score matching was used to correct for differences in baseline characteristics between the two groups. After propensity score matching, the metastasis pattern, including metastasis sites and timing, was compared and analyzed.
RESULTS
RESULTS
After propensity score matching, there were 408 patients in the PCRT group and 245 patients in the NCRT group. NCRT significantly reduced local recurrence (4.1% vs. 10.3%, P = 0.004), but not distant metastases (28.2% vs. 27.9%, P = 0.924) compared with PCRT. In both the NCRT and PCRT groups, the most common metastasis site was the lung, followed by the liver. The NCRT group developed local recurrence and distant metastases later than the PCRT group (median time: 29.2 [18.8, 52.0] months vs. 18.7 [13.3, 30.0] months, Z = -2.342, P = 0.019; and 21.2 [12.2, 33.8] vs. 16.4 [9.3, 27.9] months, Z = -1.765, P = 0.035, respectively). The distant metastases occurred mainly in the 2nd year after surgery in both the PCRT group (39/114, 34.2%) and NCRT group (21/69, 30.4%). However, 20.3% (14/69) of the distant metastases appeared in the 3rd year in the NCRT group, while this number was only 13.2% (15/114) in the PCRT group.
CONCLUSIONS
CONCLUSIONS
The predominant site of distant metastases was the lung, followed by the liver, for both the NCRT group and PCRT group. NCRT did not influence the predominant site of distant metastases, but the NCRT group developed local recurrence and distant metastases later than the PCRT group. The follow-up strategy for patients with NCRT should be adjusted and a longer intensive follow-up is needed.
Identifiants
pubmed: 34553701
doi: 10.1097/CM9.0000000000001641
pii: 00029330-202109200-00009
pmc: PMC8478402
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2196-2204Informations de copyright
Copyright © 2021 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.
Références
National Comprehensive Cancer Network: NCCN Guidelines: Rectal cancer. Available from: https://www.nccn. org/professionals/physician_gls/pdf/rectal.pdf . [Accessed December 10, 2020]
Zhang Y, Sun Y, Xu Z, Chi P, Lu X. Is neoadjuvant chemoradiotherapy always necessary for mid/high local advanced rectal cancer: a comparative analysis after propensity score matching. Eur J Surg Oncol 2017; 43:1440–1446. doi: 10.1016/j.ejso.2017.04.007.
doi: 10.1016/j.ejso.2017.04.007
Arredondo J, Baixauli J, Beorlegui C, Arbea L, Rodríguez J, Sola JJ, et al. Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy. Dis Colon Rectum 2013; 56:416–421. doi: 10.1097/DCR.0b013e318274d9c6.
doi: 10.1097/DCR.0b013e318274d9c6
Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351:1731–1740. doi: 10.1056/NEJMoa040694.
doi: 10.1056/NEJMoa040694
Roth ES, Fetzer DT, Barron BJ, Joseph UA, Gayed IW, Wan DQ. Does colon cancer ever metastasize to bone first? A temporal analysis of colorectal cancer progression. BMC Cancer 2009; 9:274doi: 10.1186/1471-2407-9-274.
doi: 10.1186/1471-2407-9-274
Tan KK, Lopes Gde L Jr, Sim R. How uncommon are isolated lung metastases in colorectal cancer? A review from database of 754 patients over 4 years. J Gastrointest Surg 2009; 13:642–648. doi: 10.1007/s11605-008-0757-7.
doi: 10.1007/s11605-008-0757-7
Chau I, Allen MJ, Cunningham D, Norman AR, Brown G, Ford HE, et al. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol 2004; 22:1420–1429. doi: 10.1200/JCO.2004.05.041.
doi: 10.1200/JCO.2004.05.041
Ikoma N, You YN, Bednarski BK, Rodriguez-Bigas MA, Eng C, Das P, et al. Impact of recurrence and salvage surgery on survival after multidisciplinary treatment of rectal cancer. J Clin Oncol 2017; 35:2631–2638. doi: 10.1200/JCO.2016.72.1464.
doi: 10.1200/JCO.2016.72.1464
Ding P, Liska D, Tang P, Shia J, Saltz L, Goodman K, et al. Pulmonary recurrence predominates after combined modality therapy for rectal cancer: an original retrospective study. Ann Surg 2012; 256:111–116. doi: 10.1097/SLA.0b013e31825b3a2b.
doi: 10.1097/SLA.0b013e31825b3a2b
Watanabe K, Saito N, Sugito M, Ito M, Kobayashi A, Nishizawa Y. Predictive factors for pulmonary metastases after curative resection of rectal cancer without preoperative chemoradiotherapy. Dis Colon Rectum 2011; 54:989–998. doi: 10.1007/DCR.0b013e31821b9bf2.
doi: 10.1007/DCR.0b013e31821b9bf2
Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73:2680–2686. doi: 10.1002/1097-0142(19940601)73:11<2680::aid-cncr2820731105>3.0.co;2-c.
doi: 10.1002/1097-0142(19940601)73:11
Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997; 12:19–23. doi: 10.1007/s003840050072.
doi: 10.1007/s003840050072
Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003; 98:1521–1530. doi: 10.1002/cncr.11660.
doi: 10.1002/cncr.11660
Rödel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005; 23:8688–8696. doi: 10.1200/JCO.2005.02.1329.
doi: 10.1200/JCO.2005.02.1329
Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Saltz LB, et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer 2008; 113:57–64. doi: 10.1002/cncr.23516.
doi: 10.1002/cncr.23516
Mirbagheri N, Kumar B, Deb S, Poh BR, Dark JG, Leow CC, et al. Lymph node status as a prognostic indicator after preoperative neoadjuvant chemoradiotherapy of rectal cancer. Colorectal Dis 2014; 16:O339–O346. doi: 10.1111/codi.12682.
doi: 10.1111/codi.12682
Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 2012; 13:679–687. doi: 10.1016/S1470-2045(12)70187-0.
doi: 10.1016/S1470-2045(12)70187-0
Arredondo J, Baixauli J, Rodríguez J, Beorlegui C, Arbea L, Zozaya G, et al. Patterns and management of distant failure in locally advanced rectal cancer: a cohort study. Clin Transl Oncol 2016; 18:909–914. doi: 10.1007/s12094-015-1462-0.
doi: 10.1007/s12094-015-1462-0
Frambach P, Pucciarelli S, Perin A, Zuin M, Toppan P, Maretto I, et al. Metastatic pattern and new primary tumours after neoadjuvant therapy and surgery in rectal cancer. Colorectal Dis 2018; 20:O326–O1326. doi: 10.1111/codi.14427.
doi: 10.1111/codi.14427
Augestad KM, Keller DS, Bakaki PM, Rose J, Koroukian SM, Øresland T, et al. The impact of rectal cancer tumor height on recurrence rates and metastatic location: a competing risk analysis of a national database. Cancer Epidemiol 2018; 53:56–64. doi: 10.1016/j.canep.2018.01.009.
doi: 10.1016/j.canep.2018.01.009
Uberoi AS, Bhutani MS. Has the role of EUS in rectal cancer staging changed in the last decade. Endosc Ultrasound 2018; 7:366–370. doi: 10.4103/eus.eus_36_18.
doi: 10.4103/eus.eus_36_18
Fisher DA, Shergill AK, Early DS, Acosta RD, Chandrasekhara V, et al. ASGE Standards of Practice Committee. Role of endoscopy in the staging and management of colorectal cancer. Gastrointest Endosc 2013; 78:8–12. doi: 10.1016/j.gie.2013.04.163.
doi: 10.1016/j.gie.2013.04.163
Muthusamy VR, Chang KJ. Optimal methods for staging rectal cancer. Clin Cancer Res 2007; 13:6877s–6884s. doi: 10.1158/1078-0432.CCR-07-1137.
doi: 10.1158/1078-0432.CCR-07-1137
Merkel S, Mansmann U, Hohenberger W, Hermanek P. Time to locoregional recurrence after curative resection of rectal carcinoma is prolonged after neoadjuvant treatment: a systematic review and meta-analysis. Colorectal Dis 2011; 13:123–131. doi: 10.1111/j.1463-1318.2009.02110.x.
doi: 10.1111/j.1463-1318.2009.02110.x
Fan WH, Xiao J, An X, Jiang W, Li LR, Gao YH, et al. Patterns of recurrence in patients achieving pathologic complete response after neoadjuvant chemoradiotherapy for rectal cancer. J Cancer Res Clin Oncol 2017; 143:1461–1467. doi: 10.1007/s00432-017-2383-9.
doi: 10.1007/s00432-017-2383-9
Pan HD, Zhao G, An Q, Xiao G. Pulmonary metastasis in rectal cancer: a retrospective study of clinicopathological characteristics of 404 patients in Chinese cohort. BMJ Open 2018; 8:e019614doi: 10.1136/bmjopen-2017-019614.
doi: 10.1136/bmjopen-2017-019614
Lee JL, Yu CS, Kim TW, Kim JH, Kim JC. Rate of pulmonary metastasis varies with location of rectal cancer in the patients undergoing curative resection. World J Surg 2015; 39:759–768. doi: 10.1007/s00268-014-2870-y.
doi: 10.1007/s00268-014-2870-y